Clinical trials: Early Psychosis, open to volunteers
Psychosis
Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis
Chronic psychosis, including schizophrenia is now viewed as a progressive disorder where cognitive deficits predate the clinical onset.
- Trial name
- PSYCARE (NCT05796401)
- Testing
- Cognitive training, Personalized neuroprotective strategies : Vitamin B12, folinic acid, Omega 3, NAC, Treatment as usual (TAU)
- Where
- 13 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier St Anne
Clinical High Risk, Early Psychosis
Digital Strategies to Advance Help-Seeking Aim 1 and 2
This proposal aims to establish a Digital Laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at Clinical High-Risk (CHR) for developing psychosis.
- Conditions
- Clinical High Risk, Early Psychosis, First Episode Psychosis
- Trial name
- NCT06774430
- Where
- United States
- Volunteers
- 25,000 people
- Sponsor
- Columbia University
Psychotic Disorders, Personality Disorders
Sensory Profile and Early Clinical Signs of Calm Room Users
This descriptive study aims primarily to characterize the sensory profile of patients in a closed psychiatric hospital unit who use a calming room.
- Conditions
- Psychotic Disorders, Personality Disorders, Mood Disorders
- Trial name
- EVAL-APAISE (NCT06839950)
- Testing
- Calm room
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Esquirol
Psychoses
Adapting a Socio-cognitive Intervention to Early Psychosis Services
Social cognition (SC) is a broad term used to describe abilities we use to process/interpret emotional cues, others' and own thoughts/feelings.
- Trial name
- NCT07102784
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- King's College London
Caregiver, Caregiver Distress
mHealth for Early Psychosis Caregivers in Statewide Program Outreach
The purpose of this study is to pilot the delivery of an mHealth intervention for caregivers to young people with early psychosis within a network of early psychosis intervention programs in the state of North Carolina.
- Conditions
- Caregiver, Caregiver Distress, Caregiver to a Young Adult With Early Psychosis, Family Caregivers
- Trial name
- Bolster-NC (NCT07225179)
- Testing
- Bolster
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Psychotic Disorder
tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia
Background: In parallel to the traditional symptomatology, deficits in cognition (memory, attention, reasoning, social functioning) contribute significantly to disability and suffering in individuals with schizophrenia.
- Trial name
- STICOG (NCT05440955)
- Testing
- left fronto-temporal transcranial Direct Current Stimulation (tDCS)
- Where
- 4 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
Schizophenia Disorder, Schizoaffective Disorder
Exercise and Olanzapine-samidorphan
This is a single site trial in 30 patients with schizophrenia, schizoaffective, or bipolar I/II/NOS disorder in which all participants will receive eight weeks of olanzapine and samidorphan (Olz/Sam) plus four weeks of aerobic…
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
- Trial name
- NCT06740890
- Testing
- Olanzapine-samidorphan + exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- New York State Psychiatric Institute
First Episode Psychosis (FEP), Clinical High Risk for Psychosis (CHR)
Reducing the Duration of Untreated Psychosis in the United States: The Impact of Screening and Systematic Communication
The goal of this project is to investigate whether a systematic screening approach enhanced by an innovative model of communicating information about psychosis and treatment options to patients and families (ComPsych) can reduce…
- Trial name
- EaSIE (NCT05509998)
- Testing
- Screening Method (SM), Screening and Communication Method (SCM)
- Where
- United States
- Volunteers
- 912 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia Disorders
An Integrated Neurophysiological Approach Toward the Early Detection of Psychiatric Disorders
Schizophrenia (SCZ) is a severe neuropsychiatric disorder characterized by cognitive decline, social withdrawal, and positive symptoms such as hallucinations and delusions.
- Trial name
- NCT06886945
- Testing
- Audio-Visual Perceptual Tasks
- Where
- Italy
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro San Giovanni di Dio Fatebenefratelli
Psychosis
Culturally Adapted Psychosocial Interventions for Early Psychosis in a Low-resource Setting
Primary Aims: To determine the clinical efficacy of Culturally adapted Cognitive Behavioral Therapy (CaCBT) and Culturally adapted Family Intervention (CulFI) compared to Treatment As Usual (TAU) on reducing overall symptoms of…
- Trial name
- CaPSI (NCT05814913)
- Testing
- CaCBT for psychosis, Culturally adapted Family Intervention (CulFI) for psychosis
- Where
- Pakistan
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Pakistan Institute of Living and Learning
Schizophrenia, Psychotic Disorders
Dimensional and Developmental Profiles of Psychosis in Children and Adolescents
Five collaborating sites in France will study the broad spectrum of schizophrenia in children and adolescents. Patients will be studied with diagnostic interviews, developmental histories, dimensional clinical ratings…
- Trial name
- PSYDEV (NCT04370730)
- Testing
- clinical, neuroimaging and DNA assessments
- Where
- 6 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Psychosis, First Episode Psychosis
Stratification and Treatment in Early Psychosis Study - ENHANCE
The purpose of this study is: To investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD) to the existing treatment, compared to placebo, in participants with a first episode of…
- Conditions
- Psychosis, First Episode Psychosis, Psychotic Disorders, Psychotic Episode
- Trial name
- STEP-ENHANCE (NCT06778564)
- Testing
- CBD 100 mg/mL Oral Solution
- Where
- 17 sites in Austria, Germany and 7 more
- Volunteers
- 250 people
- Sponsor
- University of Oxford
Psychosis, Alcohol Use Disorder
Piloting of an Intervention to Reduce Problematic Alcohol Use in Early Phase Psychosis Patients
A focus of research for youth and Emerging Adults with early phase psychosis (EPP) has been cannabis use. However, this focus has led to overlooking the possible negative influence of another legal recreational drug, alcohol.
- Trial name
- NCT05365347
- Testing
- Cognitive Enhancement Therapy (CET)
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Nova Scotia Health Authority
Schizophrenia
A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute…
- Trial name
- NCT07734493
- Testing
- LTX-001 once daily, LTX-001 twice daily
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Leal Therapeutics, Inc
Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis
Stratification and Treatment in Early Psychosis Study - PROMOTE
The purpose of this trial is: To investigate whether cannabidiol (CBD), compared to placebo, can reduce the severity of attenuated psychotic symptoms in individuals at clinical high risk for psychosis.
- Conditions
- Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
- Trial name
- STEP-PROMOTE (NCT07434973)
- Testing
- Cannabidiol (CBD)
- Where
- 19 sites in Austria, Canada and 8 more
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Schizophrenia
Enhancing Prefrontal Oscillations and Working Memory in Early-course Schizophrenia
This study will investigate the effects of intermittent Theta Burst Stimulation (iTBS) on natural oscillatory frequency of the dorsolateral prefrontal cortex (DLPFC) and working memory in early-course schizophrenia (EC-SCZ).
- Trial name
- REDOCS (NCT05102929)
- Testing
- active intermittent Theta Burst Stimulation (iTBS)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Fabio Ferrarelli
Psychosis; Acute
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and…
- Trial name
- CINEMA (NCT07483294)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Schizophrenia
Evaluation of the Individual Early Psychoeducation Program for Schizophrenic Disorders in Inpatients
Schizophrenia affects about 0.7% of the population. Poor insight, which is common in this disease, linked to poor drug compliance is leads to rehospitalisation with major impact on quality of life.
- Trial name
- PEPITS (NCT05329363)
- Testing
- PEPITS Programme, Usual care
- Where
- 11 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Tours
Clinical High Risk for Psychosis (CHR)
A Multimodal Imaging Study of Dopamine in Early Psychosis
The development of new treatments for psychosis, a psychiatric condition that is prevalent and highly disabling despite antipsychotic medications, has been limited, in part, by a lack of information from brain imaging studies…
- Trial name
- MISDEP (NCT06977308)
- Testing
- Methylphenidate (MPH), [11C]raclopride
- Volunteers
- 115 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
A 20-Year Follow-up of First Episode Psychosis: Longitudinal Effects of Early Treatment Strategies and Relapse
The study aims to address the following questions: 1. Do subgroups defined by early medication choices, relapse, and medication taken over 20 years differ in clinical, cognitive, and functional outcomes? 2.
- Trial name
- NCT07616999
- Where
- China
- Volunteers
- 178 people
- Sponsor
- The University of Hong Kong